Lilly to see leadership transitions in diabetes/obesity business
US pharma major Eli Lilly (NYSE: LLY) today revealed that Mike Mason, executive vice president and president of Lilly Diabetes and Obesity, will retire at the end of 2023 after 34 years with the company.
The move comes just as Lilly anticipates an FDA weight loss approval by year-end for its in-demand diabetes drug Mounjaro (tirzepatide, which would then compete in the massive therapy sector with Danish firm Novo Nordisk (NOV: N) already marketed Wegovy (semaglutide).
Over the last two decades, Mr Mason has served in the leadership of Lilly's Neuroscience and Diabetes businesses to achieve significant growth and leading market positions. Over the last four years at the helm of Lilly Diabetes and Obesity, Mr Mason has overseen tirzepatide's late-stage development and unprecedented diabetes launch while establishing and preparing the company's obesity franchise for its anticipated launch.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze